Background Thalassemia is a common genetic disease in Southeast Asia. Red blood cell
(RBC) transfusion is an essential treatment for severe forms of thalassemia. We performed a …

BACKGROUND Hemoglobin E‐β0 thalassemia and homozygous β0‐thalassemia are the
most common chronic transfusion‐dependent thalassemias in Thailand. Patients with these …

Patients with beta thalassemia major (TM) are transfusion-dependent (TD) since early
childhood and for life. Development of alloantibodies and autoantibodies against red blood …

Life-long red blood TRANSFUSION remains the main treatment for severe THALASSEMIA.
The development of hemolytic alloantibodies and erythrocyte autoantibodies complicated …

BACKGROUND β‐Thalassemia is considered the most common chronic hemolytic anemia
in Egypt. Alloimmunization can lead to serious clinical complications in transfusion …

Background: The development of anti-red blood cell antibodies (both allo-and
autoantibodies) remains a major problem in thalassemia major patients. We studied the …

The development of hemolytic alloantibodies and erythrocyte autoantibodies complicates
transfusion therapy in thalassemia patients. The frequency, causes, and prevention of this …

BACKGROUND: Red blood cell (RBC) alloimmunization is reported to occur at an incidence
of 5.2% to 23.5% among patients with thalassemia requiring chronic transfusion. With very …

BACKGROUND: Thalassemia is considered the most common hemoglobinopathy in Egypt
and is one of its major health problems. Lifelong red blood cell (RBC) transfusion remains …

Background Red blood cell (RBC) alloimmunization is a major challenge to repeated
transfusions in β-thalassemia-major patients. The aim of this study was to evaluate the …